Clinical trials for Rectal cancer
205 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04116541
#2023-510567-35-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04116541
#2023-510567-35-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
Sarcoma and GIST
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT07303387
#2024-519788-16-00
Efficacité et innocuité du valémétostat chez les patients atteints de tumeurs solides sélectionnées.
Cohorte 1.Cb (Défience en ARID1A-defective, autres tumeurs)
Required disease stage
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Stomach and esophageal cancer
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT06333314
#2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
6 recruiting sites
UNICANCER
Phase 2
Colon cancer
Rectal cancer
#NCT07221357
#2025-523224-45-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
MSI/dMMR
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
12 recruiting sites
Bristol-Myers Squibb
Phase 2
Colon cancer
Rectal cancer
Anal cancer
#NCT04954820
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
1
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
26 recruiting sites
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2
Colon cancer
Rectal cancer
Anal cancer
#NCT04268121
#2024-515603-19-01
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
10 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
#NCT06760819
#2024-517419-62-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Ampullary carcinoma
Gastrointestinal stromal tumor
Squamous cell carcinoma
Other
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Bayer
Phase 2
Colon cancer
Rectal cancer
#NCT07071844
#2024-520128-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2
Colon cancer
Rectal cancer
#NCT06646445
#2023-509322-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
1 recruiting site
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie